IRCT20171030037093N20
Recruiting
Phase 2
Evaluation of the Optimal Dosage for the Efficacy of Submucosal Midazolam Administration to Induce Sedation in Children Undergoing Diagnostic Procedures
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 99
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 3 months to 5 years (—)
- Sex
- All
Inclusion Criteria
- •The age range of over three months up to five years
- •Children requiring diagnostic procedures such as CT scan
Exclusion Criteria
- •The patients with excessive sensitivity to Benzodiazepines
- •Medical disorder of shock or blood pressure
- •Alcohol intoxication
- •Poor vital signs
- •Pulmonary diseases
- •Myasthenia gravis or musculoskeletal disorders
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
Active, not recruiting
Not Applicable
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
Active, not recruiting
Phase 1
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001292-39-ESab Servier116
Active, not recruiting
Phase 1
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years.Paediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 16.0 Level: LLT Classification code 10008908 Term: Chronic heart failure System Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001292-39-GBInstitut de Recherches Internationales Servier116
Active, not recruiting
Phase 1
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-BGInstitut de Recherches Internationales Servier90